Cancer Research UK, EPSRC partner to fund multidisciplinary cancer research projects

Cancer Research UK has partnered with the Engineering and Physical Sciences Research Council (EPSRC), to co-fund multidisciplinary research projects.

The new partnership increases the amount of funding for collaborative research to up to £37.5 million over five years. Joint awards will be issued by Cancer Research UK, with the first awards decided this April. The move builds on the high level of interest in the charity's Multidisciplinary Project Award Scheme launched in August 2014.

The EPSRC is the main UK funding agency for training and research in engineering and physical sciences. Working with the EPSRC will not only increase support for collaborative cancer research projects, but will also unite the expertise and scientific networks of both organisations, to ensure that the highest quality multidisciplinary work will be funded.

The move will also stimulate innovation and combine disciplines to accelerate progress in cancer research. Multidisciplinary projects are already showing much promise. At Oxford University, Cancer Research UK scientists across different areas of expertise are working on new treatment technologies for prostate cancer. They are developing imaging techniques coupled with new fluorescent probes that make it easier for surgeons to distinguish prostate cancer from normal tissue during surgery - improving patient outcomes.

Cancer Research UK and the EPSRC want to inspire more research like this to improve our understanding of cancer, and boost innovation in cancer diagnosis and treatment.

Professor Sir Mike Brady at the University of Oxford, who will chair the expert review committee, said: "This partnership will provide exciting opportunities and increases the number of projects we can fund. We need to push the boundaries, exploring the integration of engineering and physical sciences into cancer research. Combining these two communities will inspire new ways to translate science into patient benefit."

Professor Philip Nelson, chief executive of the Engineering and Physical Sciences Research Council, said: "This new partnership will build further on our existing collaborative work which is already reaping rich rewards for scientists, engineers, clinicians and of course, patients. We are confident that the strength of these collaborations will inspire more researchers to work with Cancer Research UK, EPSRC and other partners. This partnership will help the UK acquire tools and skills we need in our collective battle against cancer."

Dr Iain Foulkes, Cancer Research UK's executive director of strategy and research funding, said: "We're delighted to build on our existing relationship with the EPSRC. We've made great progress, with cancer survival rates doubling over the last 40 years, but solving the challenges of cancer prevention, diagnosis and treatment will require multidisciplinary collaboration both within the biomedical arena and with other disciplines. Invigorating new ideas and the development of novel techniques through innovative collaborations with engineers and physical scientists will really help drive cancer research forwards so that we can benefit more patients sooner."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine shows potential in preventing recurrence of triple-negative breast cancer